Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

NCT03833167 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC